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In light of the reemergence of pertussis (whooping 
cough), the pioneering research of Pearl Kendrick and 
Grace Eldering is worth revisiting. In the 1930s, working 
in the Michigan Department of Health laboratory in Grand 
Rapids, Michigan, USA, they began researching a pertussis 
vaccine. Their research offers an instructive case study of 
the creative public health research performed in state health 
department laboratories during the interwar years. State de-
partment of health laboratory directors actively promoted re-
search by supporting advanced education; making facilities 
and funding available for individual projects; and, when pos-
sible, procuring new facilities. Using Michigan Department 
of Health resources and local and federal funding, Kend-
rick and Eldering developed standardized diagnostic tools; 
modiﬁ  ed and improved extant vaccines; conducted the ﬁ  rst 
successful, large-scale, controlled clinical trial of pertussis 
vaccine; and participated in international efforts to standard-
ize and disseminate the vaccine. Their model may again 
offer a promising avenue for groundbreaking research.
I
n light of the reemergence of pertussis (whooping cough), 
the pioneering pertussis vaccine research conducted by 
Drs Pearl Kendrick and Grace Eldering (Figure) at the 
Michigan Department of Health laboratory is worth revisit-
ing. Their pertussis research offers a model that would be 
useful today.
Although scientists had developed vaccines to control 
many infectious diseases including smallpox, typhoid fe-
ver, diphtheria, and tetanus by the 1920s, whooping cough 
proved a more difﬁ  cult puzzle. French researchers Bordet 
and Gengou described Bordetella pertussis as the causative 
agent of whooping cough in 1906 (1). In the 1920s, phar-
maceutical companies in the United States offered many 
pertussis and mixed-serum pertussis vaccines designed to 
both treat and prevent whooping cough, but none proved 
effective (2). In 1931, the American Medical Association’s 
Council on Pharmacy and Chemistry found no “evidence 
even for the presumptive value of stock or commercial vac-
cines” because “the pertussis vaccines seem to have abso-
lutely no inﬂ  uence [as a preventive], and after the disease 
is thoroughly established even freshly prepared vaccines 
seem useless” (3).
By the 1920s, pertussis had claimed the lives of ≈6,000 
US children each year, more than did each of the childhood 
scourges of diphtheria, scarlet fever, and measles (4). Thor-
vald Madsen of the Danish Serum Institute in Copenhagen 
spurred further pertussis research when he announced that 
his vaccine prepared from freshly isolated B. pertussis cul-
tures offered some protection in his Faroe Islands studies 
in the 1920s (5). English scientists P. H. Leslie and A. D. 
Gardner described 4 antigenic groups or phases for B. per-
tussis and highlighted the importance of selecting appropri-
ate cultures for vaccine production in 1931 (6). Illinois pe-
diatrician Louis Sauer and his assistant Leonora Hambrecht 
conducted smaller scale tests of their effective vaccine (4). 
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Still, the disease remained a killer (7). In 1932, when Kend-
rick and Eldering began their research at the Michigan De-
partment of Health laboratory in Grand Rapids, Michigan, 
USA, many questions remained unanswered.
Starting in the mid-19th century, public health leaders 
across the nation developed city and state departments of 
health. When bacteriology was introduced in the late 19th 
century, these health departments gradually shifted their 
mission from promoting general sanitation to public health 
efforts that targeted the speciﬁ  c vectors of disease and fo-
cused on laboratory diagnosis (8–10). By 1915, most major 
cities and all states had invested in laboratory facilities ded-
icated to bacteriologic analysis, biologics production, and 
(in many) fundamental research (10,11). After World War 
I, state health department laboratory directors expanded 
their laboratory divisions with funds newly available from 
the federal government, the American Public Health As-
sociation (APHA), and the Rockefeller Foundation (9,10). 
For Charles Chapin, Superintendent of Health for Provi-
dence, Rhode Island, however, most of these laboratories 
had not reached their potential because of limited funds and 
personnel. “On the whole,” he noted, “investigation of the 
sources of diseases has not attained very brilliant results in 
the hands of most state health departments, as their ener-
gies have been largely forced into other channels whether 
they wished it or not” (10).
To staff their growing departments and stay within 
their limited budgets, laboratory directors often sought out 
talented female scientists. Pearl Kendrick, from her days as 
a student and teacher in upstate New York, was recognized 
by her teachers as being “a ﬁ  rst class student, thorough, ac-
curate and rapid” (12). While teaching, she continued her 
own education, studying bacteriology at Columbia Univer-
sity under Hans Zinsser during the summer of 1917 (12). 
After Kendrick had worked for 2 years as an assistant at the 
New York State Department of Health laboratories, C.C. 
(Cy) Young, director of the Bureau of Laboratories for the 
Michigan Department of Health, recruited her. Young as-
sured Kendrick that “I’m sure that we can make it interest-
ing for you and there is every chance for advancement” 
(12). In 1926, Young assigned Kendrick to direct the health 
department’s newly opened Grand Rapids branch. Young 
provided his employees funding and time to pursue ad-
vanced education. In 1932, Kendrick earned a Doctor of 
Science degree in bacteriology from Johns Hopkins Uni-
versity. Young’s strategy of pursuing talent, supporting ad-
vanced education, and funding research paid dividends. By 
the late 1920s, Young’s Bureau of Laboratories in Lansing 
and Grand Rapids had established a national reputation for 
bacteriologic research.
Grace Eldering, Kendrick’s laboratory partner, hailed 
from eastern Montana. Eldering studied at the University 
of Montana in Missoula and taught English and biology at 
Hysham High School for a year after graduation before an-
swering the Michigan Bureau of Laboratories’ call for addi-
tional staff. In the fall of 1928, Eldering traveled to Lansing 
to take advantage of this opportunity. Within 6 months, she 
was hired into the department to do routine bacteriologic 
analysis. Eldering would earn her Doctor of Science degree 
from Johns Hopkins University in 1942 (13).
In 1932, Kendrick brought Eldering to Grand Rap-
ids, and, when a virulent strain of B. pertussis infected the 
children of Grand Rapids that year, Kendrick and Elder-
ing began the whooping cough research project. The state 
laboratory gave Kendrick and Eldering the freedom to 
conduct their research after all of the laboratory’s routine 
water and milk analyses were completed. They developed 
and improved methods for growing the pertussis bacillus, 
inactivating it, and creating a safe vaccine (14,15). In addi-
tion, they were pioneers in the ﬁ  eld, designing and direct-
ing the ﬁ  rst large-scale controlled clinical trial for pertussis 
vaccine. In the pages of Reader’s Digest, Paul DeKruif, a 
Grand Rapids native and author of the best seller Microbe 
Hunters, celebrated their study as one of the “greatest ﬁ  eld 
tests in microbe-hunting history” (16).
To pursue their groundbreaking research, Kendrick 
and Eldering brought together a diverse coalition of local 
and state public health departments, physicians, citizens’ 
groups, women’s groups, and parent–teacher associations 
that would provide organizational support and funding. By 
building relationships with local physicians and the Grand 
Rapids Health Department, Kendrick and Eldering ensured 
a steady supply of cough plates containing B. pertussis 
samples. When city physician A.H. Edwards notiﬁ  ed them 
of pertussis infections in the community, Kendrick and El-
dering sped off to visit families hit hard by the economic 
downturn and to collect samples. As Grace Eldering noted 
in an interview, they “learned about pertussis and the De-
pression at the same time” (15). In addition, the city health 
department aided their research by allowing its network of 
public and private nurses to collect cough plates for the per-
tussis research.
During the ﬁ   rst stage of their research, Kendrick 
and Eldering modiﬁ  ed the then-standard Bordet-Gengou 
growth medium; the result was a growth medium that 
fostered more rapid and profuse growth of B. pertussis 
colonies and that could therefore be used as a routine 
diagnostic tool (15). On November 1, 1932, Kendrick’s 
laboratory began offering a cough plate diagnostic ser-
vice to local doctors. In addition to aiding the doctors, the 
rapid-growth plates enabled Kendrick and Eldering to de-
termine that during the ﬁ  rst 3 weeks of infection, a child’s 
cough contained enough active pertussis bacilli to infect 
his or her peers; that most children were noninfectious by 
week 4; and that after 5 weeks, 90% of the children posed 
no risk to others (17).
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Proper quarantine length could now be determined sci-
entiﬁ  cally. Before these studies, whooping cough quaran-
tines varied from 2 to 4 weeks, depending on locale. The 
Grand Rapids Health Department adopted Kendrick and 
Eldering’s quarantine recommendations, which required 
physicians to report the disease; ordered the health depart-
ment to place warning placards on homes; and enforced 
a 35-day isolation period or, with 2 consecutive negative 
cough plates, release by day 28 after onset of symptoms 
(18). As Pearl Kendrick noted in 1934, these “regulations 
have crystallized out of our bacteriological studies and are 
now under test as part of the Grand Rapids Communicable 
Disease Regulations” (19). In 1935, Kendrick reported that 
the “cough plate technic [sic] has become a routine proce-
dure in the laboratory”; that year, Kendrick’s Michigan De-
partment of Health laboratory in Grand Rapids examined 
4,515 cough plates for B. pertussis (20).
After several months of producing autogenous vac-
cines for local physicians to use as treatment and preven-
tive, Kendrick appealed to state laboratories director Cy 
Young for permission to develop a more general vaccine. 
“Rather than handl[ing] each request on the basis of an 
autogenous vaccine,” Kendrick explained to Young on 
February 4, 1933, “we can more efﬁ  ciently make a sup-
ply from several local pertussis strains.” She then asked: 
“May we do this on an experimental basis—supplying 
these few pediatricians who are the type to cooperate as to 
records [?]” (12). Young supported her efforts. In a hand-
written note dated February 21, 1933, he told Kendrick: 
“Go ahead and do all you can with pertussis if it amuses 
you” (12).
Kendrick and Eldering performed carefully controlled 
animal studies of vaccines, using the general methods of 
Madsen, Sauer, and Hambrecht to design a vaccine that 
was safer and more potent (15). They inactivated the per-
tussis bacilli with thimerosol at cold room temperature for 
>1 week and conducted numerous sterility and safety tests 
(including injecting the vaccine into their own arms to test 
for safety) (12,14,15). After these vaccines were declared 
safe, they were distributed to local physicians who, in re-
turn for the serum, supported Kendrick and Eldering’s lab-
oratory work by spreading the news of the vaccine to area 
medical personnel and encouraging wider use of diagnostic 
cough plates (12).
Recruiting study participants and gathering ﬁ  nancial 
support for a wide-scale vaccine trial required concerted 
community outreach efforts (18,20). In a 1958 retrospective 
on their ﬁ  eld studies, Grace Eldering noted that “among the 
many who contributed to the success of the program were 
the parents and their children who accepted the require-
ments for test and control groups in the ﬁ  eld trials. This ac-
ceptance was basic, and laid a foundation in the community 
upon which other studies could be built” (21).
In the 1930s, there were no accepted standards and few 
established models for conducting ﬁ  eld studies, a problem 
made clear in failed experiments with human participants, 
including the Brodie-Park and Kolmer polio trials in the 
1930s (22). Many researchers used orphans or institutional-
ized children for their research, noting that by participating, 
these children were repaying a debt to society (23). Instead 
of relying on these vulnerable populations, Kendrick and 
Eldering built outreach networks during the early stages 
of their research. The Kent County Welfare Relief Com-
mission aided these efforts by collecting statistics on the 
prevalence of whooping cough and the number of children 
who had received “a treatment to prevent whooping cough” 
in their 1935 vaccination survey. This study of vaccination 
of preschool-aged children and the careful records of the 
city health department’s nursing districts enabled Kendrick 
and Eldering to select controls matched for age, sex, and 
district (12).
Private physicians joined school physicians and city 
health ofﬁ  cials in administering the series of 4 or 5 shots 
at the vaccination clinics held in primary schools around 
the city, federally funded nursery schools, and at City Hall 
(12,24). For each child in the study, city health department 
nurses completed a vaccine inoculation form, a home visit 
slip, an exposure record, and a case history; the research-
ers matched each inoculated child with a control selected 
from the Kent County Welfare Relief Commission study. 
At 3–4-month intervals, the nurses visited children in both 
groups and collected information about exposures; checked 
patients for the bacillus with cough plates; and when need-
ed, obtained case histories for exposures and illness (14). 
The 1934–1935 ﬁ  eld trial involved 1,592 (712 vaccinated 
and 880 control) children. In their 1935 report to the APHA, 
Kendrick noted that only 4 of the 712 vaccinated children 
had whooping cough, and then only mild cases, but 45 of 
the 880 unvaccinated controls (90% of those exposed) con-
tracted the disease and suffered its full ravages. Despite the 
89% efﬁ  cacy rate found in the trial, they cautioned against 
the “danger of giving [the numbers] too much weight in 
the face of the relatively small number of whooping cough 
cases” (14).
Before the large-scale federal ﬁ  nancing of science that 
emerged after World War II, scientists were often forced 
to cobble together funds from private and public sources 
(25). Kendrick and Eldering conducted their research on a 
shoestring budget. The Michigan Department of Health al-
lowed them to use laboratory facilities after hours for their 
early pertussis research, and for the ﬁ  rst 2 years of their 
studies, a total of $1,250 arrived from private citizens, the 
Grand Rapids City Commission, and the National Research 
Council. Later, and only after their vaccine showed prog-
ress, did they receive additional funding for stafﬁ  ng and re-
search from the Federal Emergency Relief Administration 
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(a New Deal Agency) and from the Michigan Department 
of Health (15). When, in early 1936, the whooping cough 
vaccine project’s funds again ran low, Kendrick invited El-
eanor Roosevelt to visit their laboratory. Roosevelt helped 
secure the funds needed to add several Works Progress 
Administration workers to Kendrick and Eldering’s staff. 
In 1938, the Works Progress Administration furnished ad-
ditional clerical staff, and the APHA helped defray the cost 
of statistical analysis (26). Funding from all sources for the 
study amounted to $181,695.60 (12). Later, the National 
Institutes of Health would fund additional pertussis studies, 
and the Michigan Department of Health would continue 
funding public health research into the 1980s.
That Kendrick and Eldering crafted a well-controlled 
trial is revealed in their successful defense of their research 
against the skepticism of public health leaders. Soon af-
ter they announced their vaccine results, James Doull, a 
prominent Cleveland epidemiologist, reported that children 
received no protection from his whooping cough vaccine. 
The APHA subcommittee on whooping cough, which in-
cluded both Kendrick and Doull, evaluated the divergent 
results of the 2 studies. Unable to explain the difference in 
results, committee members then enlisted Wade Hampton 
Frost, a Johns Hopkins University epidemiologist and head 
of the APHA, to review the work. Although predisposed 
to ﬁ  nd fault with Kendrick’s work because of his belief 
that few studies could meet strict standards of control (12), 
Frost journeyed twice to Michigan to inspect Kendrick’s 
ﬁ  ndings and, in the end, supported her work. Frost noted to 
Kendrick, “I think it may be assumed, not as a conclusion 
but merely as a working hypothesis, that your data when 
ﬁ  nally analyzed are likely to show some protection in the 
vaccinated group. Therefore, without accepting this as a 
conclusion, I think it is proper to make plans for further 
work based on this presumption, and I would suggest two 
additional projects” (12). Had Frost not died shortly there-
after, this productive collaboration might have continued 
(27,28).
Encouraged by the results of the 1936 trials, parents 
in Grand Rapids ﬂ  ocked to enroll their children in Kend-
rick and Eldering’s 1938 follow-up study in which children 
were given smaller doses of the pertussis vaccine, adminis-
tered in 3 injections. This new regimen was found to be as 
effective as the 4 injections given in the original study (29). 
On the basis of this study, the Michigan Department of 
Health Biologic Products Division began mass-producing 
the pertussis vaccine for children in Michigan in 1938, and, 
by 1940, pertussis vaccine was widely distributed across 
the nation.
In 1943, the American Academy of Pediatrics ap-
proved the vaccine for routine use; a year later, the Ameri-
can Medical Association recommended its use (30). The 
nation’s whooping cough incidence and death rates would 
drop dramatically. In 1934, the whooping cough incidence 
in the United States was 209 cases/100,000 residents, and 
the death rate was 5.9/100,000. By 1948, routine use of the 
vaccine reduced the incidence to 51 cases/100,000 residents 
and the death rate to <1/100,000. After 1960, incidence was 
<10 cases/100,000 residents (31).
In the early 1940s, Kendrick’s Michigan Department of 
Health laboratory participated actively in APHA Pertussis 
Study Group studies designed to standardize the pertussis 
vaccine (28). At this juncture, the public health community 
used adherence to a manufacturing process as the standard 
measure of their vaccine’s safety and efﬁ  ciency, despite the 
fact that methods of inactivating the bacillus and manufac-
turing the vaccine varied widely. Before advocating wider 
dissemination of the vaccine, the APHA Pertussis Study 
Group worked closely with Kendrick and pharmaceutical 
companies to develop measurable standards and veriﬁ  able 
tests that could be applied to the end product regardless 
of the manufacturing process used. As Kendrick noted on 
March 16, 1942, to W.A. Feirer of Sharpe and Dohme, 
“May I repeat that in relation to the work of your commit-
tee on standards, it seems to me that the problem of ﬁ  rst im-
portance is to attempt to reach some degree of uniformity in 
judging the concentration of the organisms in the product. 
This does not mean necessarily that the same method of 
standardization be used by all manufacturers. It does mean 
that it should be possible to check their labeled concen-
trations within an accepted range of variation, by a single 
method” (13). Using APHA and pharmaceutical company 
funding, Kendrick and Eldering developed an opacity stan-
dard by adjusting “the turbidity of a suspension of Pyrex 
glass particles to be equivalent to that of a speciﬁ  ed number 
of bacteria of an aged vaccine determined by direct count” 
(32,33). In 1946, the United States adopted this standard; 
in 1958, the World Health Organization designated it as the 
international standard.
Although the American medical community readily 
adopted Kendrick and Eldering’s whooping cough vaccine, 
the editor of the British Medical Journal expressed more 
skepticism, arguing that none of the American studies used 
proper control groups and that their own trials had shown 
such vaccines to be ineffective (34). David Evans of the 
British Medical Research Council (MRC) and J.S. Wilson 
of the London School of Hygiene did not share the British 
Medical Journal’s concerns; indeed, they turned to Pearl 
Kendrick to assist with the MRC’s next series of studies. 
Kendrick not only supplied the British with American se-
rum to compare with the British vaccines and assisted in 
designing their study but also, with MRC funding, tested 
the potency of the vaccines, by using a mouse protection 
assay developed in the Grand Rapids laboratory, before the 
vaccines were used in the MRC ﬁ  eld trials (13,35). In the 
1950s, the World Health Organization and the Whooping 
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Cough Immunization Committee of the MRC funded Ken-
drick’s trip to England so that she could review the MRC’s 
pertussis vaccine ﬁ  eld trials (35).
Over the course of their careers, Kendrick and Eldering 
published >60 articles in a wide variety of journals, includ-
ing the American Journal of Public Health, the Journal of 
Infectious Diseases, the American Journal of Hygiene, the 
Journal of Bacteriology, the Journal of Pediatrics, and the 
Journal of Laboratory and Clinical Medicine; they received 
frequent requests for reprints (13). Kendrick’s thick corre-
spondence ﬁ  les make clear that they shared their vaccines, 
plates, cultures, and research with scientists around the 
world and hosted many international visitors in their labora-
tory. Kendrick traveled the world, often as a consultant for 
the World Health Organization, helping to establish vaccine 
programs in Mexico, eastern Europe, and Central and South 
America. In 1962, she served as part of an exchange delega-
tion on immunology to the Soviet Union (13,35).
Kendrick and Eldering participated actively in the 
inner circles of the international bacteriology and public 
health communities. Indeed, they were well known in sci-
entiﬁ  c circles for their gracious hospitality at the dinner 
parties and picnics they hosted at their Grand Rapids home 
(13). Still, they did not seek the traditional rewards of fame, 
despite the many opportunities offered later in life. Indeed, 
they actively shunned publicity, turning down opportuni-
ties to appear on the Today Show as so much attention was, 
in the words of Grace Eldering, “embarrassing” (36).
Shortly after Kendrick’s death, Dean Richard Rem-
ington, writing in the University of Michigan’s School of 
Public Health newsletter, noted:
A life saved by prevention cannot even be 
identiﬁ  ed. Who are the men and women living 
today who would be dead from whooping cough 
had it not been for Pearl Kendrick’s vaccine? 
We can conclude with reasonable certainty that 
several hundred thousand of them are now leading 
productive lives, in this country alone. But who are 
they? Name one. You can’t do it and neither can 
I.…The accomplishments of disease prevention are 
statistical and epidemiological. Where’s the news 
value, the human interest in that? … But a public 
service orientation can provide more than ample 
compensation. Dr. Kendrick never became rich 
and, outside a relatively small circle of informed 
friends and colleagues, never became famous. All 
she did was save hundreds of thousands of lives at 
modest cost. Secure knowledge of that fact is the 
very best reward (37).
In recent years, state department of health laborato-
ries have lost personnel and much of their research fund-
ing (38). Kendrick and Eldering’s model of enlisting the 
support and resources of the local, state, and national com-
munities may once again offer a promising avenue for con-
ducting groundbreaking research.
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Named for Belgian bacteriologist Jules Bordet, members of the genus Bordetella are small, gram-negative, 
aerobic coccobacilli that infect the respiratory epithelium in mammals. In 1906, Drs Bordet and Octave Gengou 
succeeded in isolating and cultivating the bacterium, later called Bordetella pertussis (from Latin per, intensive, 
and tussis, cough), which causes whooping cough, a deadly disease in young children. For this work and his 
pioneering immunologic studies, Dr Bordet was awarded the Nobel Prize in Physiology or Medicine in 1919.
Source:  Bordet J, Gengou O. Le microbe de la coqueluche. Ann Inst Pasteur (Paris). 1906;20:731–41. http://nobelprize.org; 
Dorland’s illustrated medical dictionary, 31st edition. Philadelphia: Saunders Elsevier; 2007. 